NCT05974410 2025-10-02Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer PatientsAVM Biotechnology IncAvailable
NCT01196208 2020-09-21A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001Seagen Inc.No longer available